This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02271243
Recruitment Status : Recruiting
First Posted : October 22, 2014
Last Update Posted : January 10, 2024
Sponsor:
Information provided by (Responsible Party):
Gregory Priebe, Boston Children's Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize that many of the BSIs that are currently classified as CLABSIs are actually laboratory-confirmed bloodstream infections (LCBI) that may be a result of mucosal barrier injury (MBI), also known as MBI-LCBI. In order to study this, we will isolate bacteria from multiple body sites of children that have BSI in order to compare these bacteria to the strain growing in their blood using whole-genome DNA sequencing. We will also evaluate biomarkers of MBI of the respiratory tract and GI tract.

Condition or disease
Laboratory-confirmed Bloodstream Infection Central Line-associated Bloodstream Infections Mucosal Barrier Injury

Detailed Description:
This is a prospective cohort pilot study at Boston Children's Hospital (BCH) that will explore the source of presumed CLABSI, which we believe may actually have multiple possible sources including MBI. We plan to enroll all inpatient children at BCH who meet the Centers for Disease Control and Prevention (CDC) definition of MBI-LCBI as well as children who meet the criteria for CLABSI without MBI. For all enrolled patients, we will collect samples from the oral cavity, respiratory tract, skin, and stool. These samples will be cultured in order to see if the same microbial species and strain(s) growing from the blood also grow from these other sites. Cultures will then have isolated colonies selected for whole-genome DNA sequencing to allow assessment of genomic diversity between body sites. Stool and blood samples will be tested for markers of MBI. All patient enrollment and sample collection will be done at BCH.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections
Actual Study Start Date : November 2014
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Subject with suspected MBI
Subjects without suspected MBI


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Phylogenetic relationships (on SNP scale) of bacteria isolated from different body sites [ Time Frame: Up to 2 years ]
    Phylogeny will be determined using whole-genome DNA sequences of multiple bacterial colonies that grow from each body site.


Secondary Outcome Measures :
  1. Levels of biomarkers of MBI in the blood and stool (citrulline in blood, calprotectin in stool) [ Time Frame: Up to 2 years ]
    Low citrulline and high calprotectin indicate GI tract mucosal barrier injury.


Biospecimen Retention:   Samples Without DNA
Bacteria growing from swab of oral cavity, sputum, skin, stool, and blood; stool and plasma samples.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children with CLABSI
Criteria

Inclusion Criteria:

  • Hospitalized at Boston Children's Hospital
  • Central venous catheter of any type including peripherally inserted central catheters (PICC) in any location.
  • Laboratory-confirmed bloodstream infection (LCBI) diagnosed by a clinical blood culture growing certain Gram-negative rods

Exclusion Criteria:

  • Patients with CDC-defined secondary bloodstream infections
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02271243


Contacts
Layout table for location contacts
Contact: Rachel Bernier, MPH 857-218-5348 Rachel.Bernier@childrens.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Gregory Priebe, MD    617-355-7327    Gregory.Priebe@childrens.harvard.edu   
Contact: Thomas Sandora, MD,MPH    617-355-3858    Thomas.Sandora@childrens.harvard.edu   
Principal Investigator: Gregory Priebe, MD         
Sub-Investigator: Thomas Sandora, MD, PhD         
Sub-Investigator: Jennifer Blumenthal, MD         
Sub-Investigator: Alexander McAdam, MD         
Sponsors and Collaborators
Boston Children's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Gregory Priebe, MD Boston Children's Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Gregory Priebe, Staff Physician Critical Care & Infectious Disease, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT02271243    
Other Study ID Numbers: P00012105
First Posted: October 22, 2014    Key Record Dates
Last Update Posted: January 10, 2024
Last Verified: January 2024
Keywords provided by Gregory Priebe, Boston Children's Hospital:
Central line-associated bloodstream infections
mucosal barrier injury
laboratory-confirmed bloodstream infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
Sepsis
Disease Attributes
 Pathologic Processes
Systemic Inflammatory Response Syndrome
Inflammation